Represents approximately US$500,000 in potential minimum purchases over the initial term and targets growing demand for medication temperature protection across insulin, GLP-1 therapies, biologics and other injectable medications
Toronto, Ontario -
Newsfile Corp. - October 15, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB:...
Read more: TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial...